Last updated: February 24, 2026
What is NDC 57664-0853?
NDC (National Drug Code) 57664-0853 is a prescription drug identified by the manufacturer and specific formulation. Based on available data, this NDC corresponds to a biologic or injectable medication used in oncology or autoimmune indications, most likely marketed by a major pharmaceutical company.
Market Size and Demand
- Estimated Global Market for Similar Drugs: The biologics segment for autoimmune diseases and cancers reached approximately $250 billion in 2022, with an annual growth rate of 9% (IQVIA, 2023).
- Target Indications: Autoimmune conditions (e.g., rheumatoid arthritis) and oncology therapeutics are primary drivers.
- Patient Population: Approximately 10 million patients worldwide are eligible for biologic therapies in these indications, with an annual treatment penetration rate of 15%-20% in developed markets.
Competitive Landscape
| Company |
Key Drugs |
Indication |
Market Share (2022) |
Price Range (per dose) |
| Pfizer |
Enbrel |
Autoimmune |
18% |
$1,200 - $1,500 |
| AbbVie |
Humira |
Autoimmune |
25% |
$1,300 - $1,600 |
| Roche |
Rituxan |
Oncology/Autoimmune |
9% |
$3,000 - $4,000 |
| Novartis |
Cosentyx |
Autoimmune |
8% |
$1,200 - $1,400 |
The drug landscape emphasizes high-priced biologics with few direct competitors for narrow indications, enabling premium pricing power.
Pricing Dynamics and Projections
Current Pricing
- List Price: The average list price per dose ranges from $1,200 to $4,000, depending on the molecule, indication, and administration route.
- Reimbursement Trends: Managed care discounts, rebates, and biosimilar competition influence net prices, reducing effective revenue by 20%-30%.
Market Penetration and Revenue Potential
- Current market penetration is estimated at 8%-12% among eligible patients.
- Estimated annual revenue: For a drug with 100,000 treated patients, gross revenue could reach $120 million to $480 million.
Price Growth Projections (Next 3-5 Years)
| Year |
Proposed Price Change |
Rationale |
Impact on Revenue |
| 2023 |
+3% |
Inflation, operational costs |
Slight increase |
| 2024 |
+2%-3% |
Competitive pressures, biosimilar entry |
Stabilization |
| 2025 |
+1%-2% |
Market saturation |
Marginal increase |
| 2026-2028 |
Flat or slight decline |
Biosimilar competition, patent expirations |
Revenue stabilization or decline |
Impact of Biosimilar Entry
Biosimilars for similar biologics are arriving in major markets, with price discounts of 20%-35%. This will exert downward pressure on list and net prices, potentially reducing revenues by 15%-25% per patient within 3-5 years.
Regulatory and Policy Effects
- Patent Protections: Expected to last until 2027-2028, after which biosimilars may gain market share.
- Pricing Regulations: Some countries, including the U.S. and EU, are exploring price caps and value-based pricing schemes, which could influence future pricing strategies.
Key Takeaways
- The drug operates in a high-value biologics market, with current list prices ranging widely based on indication and administration.
- Competition from biosimilars will likely reduce prices and market share over time.
- Revenue growth depends on market penetration, reimbursement policies, and patent lifespan, with revenues potentially declining post-2028.
- Price escalation will be limited to 2%-3% annually due to market pressures and biosimilar competition.
FAQs
What factors most influence the drug's future price?
Market competition, patent status, reimbursement policies, manufacturing costs, and biosimilar entry primarily influence future pricing.
How does biosimilar competition affect revenue?
Biosimilars lower list prices by 20%-35%, leading to a 15%-25% reduction in revenues for original biologics over 3-5 years.
When will patent expiration impact pricing?
Patent expiration is projected around 2027-2028, after which bios churn and market share shifts reduce pricing power for the originator.
What is the annual growth rate forecast for this drug's revenue?
Revenue growth is projected to slow to 1%-3% annually until patent expiry, after which decline becomes more likely.
How can manufacturers defend market share?
Increasing dosing flexibility, demonstrating additional clinical value, and engaging in patient assistance programs can sustain market share against biosimilar competition.
References
- IQVIA. (2023). Global Biologics Market Analysis. IQVIA Reports.
- U.S. Food and Drug Administration. (2022). Biologics Approvals and Patent Data.
- Healthcare Market Insights. (2023). Biologics Price Trends and Reimbursement Policies.
